Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474146 | 0.94 | MAP4K1 (0.34) | IDO1TDO2GABRA1GABRG2GABRB3 | |
| SCHEMBL20474229 | 0.88 | IDO1 (0.34) | IDO1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20474173 | 0.85 | IDO1 (0.32) | IDO1MAP4K1 | |
| SCHEMBL20474223 | 0.81 | IDO1 (0.35) | IDO1TDO2GABRA1GABRG2GABRB3 | |
| SCHEMBL20474202 | 0.80 | GABRA1 (0.37) | IDO1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20474181 | 0.79 | IDO1 (0.34) | IDO1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20474199 | 0.78 | IDO1 (0.35) | IDO1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20474226 | 0.77 | KDM4E (0.33) | IDO1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL22930598 | 0.76 | MAP4K1 (0.35) | IDO1MAP4K1 | |
| SCHEMBL17080354 | 0.75 | KDR (0.41) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929197-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3334736-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3929197-A1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-20180237434-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | MSR1, C1R, C1S | IDO1 175/4885TDO2 601/4885GABRA1 2310/4885 |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | CD14, MSR1, MPO | IDO1 618/4885TDO2 2197/4885GABRA1 1981/4885 |
| US-20180237434-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C1S | IDO1 175/4885TDO2 601/4885GABRA1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.